Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - protac
4
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Covalent PRC2 Inhibitors for Advanced Cancer Therapeutics
SHORT DESCRIPTION Covalent inhibitors and proteolysis-targeting chimera (
PROTAC
) degraders targeting components of the PRC2 complex (EZH and EED) to block both enzymatic and non-enzymatic functions, offering robust anti-tumor efficacy. INVENTORS Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)* Jindan...
Published: 3/17/2026
|
Updated: 3/5/2026
|
Inventor(s):
Keywords(s):
AUTM26C1
,
BIAUTM1
,
Bladder cancer
,
Breast cancer
,
Cancer/Oncology
,
Covalent inhibitor
,
Lymphoma
,
Melanoma
,
PreSeed/Seed
,
Prostate cancer
,
PROTAC
,
Small molecule
,
Targeted protein degradation
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Selective DOT1L Protein Degraders for Precision Cancer Therapy
NU 2022-081 INVENTORS Sarki Abdulkadir (PI)* Gary Schiltz (PI)* SHORT DESCRIPTION A small molecule
PROTAC
technology that degrades DOT1L protein for targeted treatment of leukemia and prostate cancer. BACKGROUND Current cancer treatments, especially for MLL-rearranged leukemia and prostate cancer, face challenges of off-target effects and...
Published: 3/17/2026
|
Updated: 2/3/2026
|
Inventor(s):
Keywords(s):
AUTM26C1
,
BIAUTM1
,
Cancer/Oncology
,
Leukemia
,
Prostate cancer
,
PROTAC
,
Small molecule
,
Targeted protein degradation
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Compounds and methods for FBXW7-R465C-mediated protein degradation
NU 2024-224 INVENTORS Xiaoyu Zhang* Ananya Basu SHORT DESCRIPTION This invention describes novel heterobifunctional compounds that exploit a somatic mutant of the FBXW7 E3 ligase for targeted protein degradation. BACKGROUND Targeted protein degradation (TPD) is a powerful therapeutic strategy that harnesses the cell's natural machinery...
Published: 2/6/2026
|
Updated: 11/18/2025
|
Inventor(s):
Keywords(s):
AUTM26_1
,
Cancer/Oncology
,
PROTAC
Category(s):
Life Sciences > Therapeutics
IDO-
PROTAC
s for Improving the Anti-Cancer Immune Response
NU 2020-137 INVENTORS Derek Wainwright* Gary Schiltz SHORT DESCRIPTION IDO-
PROTAC
that target immunosuppressive IDO activity via degradation ABSTRACT The median survival of primary GBM patients following aggressive surgical intervention, radiotherapy, chemotherapy, and tumor treating fields (TTF) is only ~14-16 months. Indoleamine 2,3-dioxygenase...
Published: 3/3/2026
|
Updated: 5/27/2022
|
Inventor(s):
Keywords(s):
AUTM26C1
,
BIAUTM1
,
Brain cancer
,
Cancer/Oncology
,
Colon cancer
,
Endometrial cancer
,
Immunotherapy
,
Pancreatic cancer
,
Prostate cancer
,
PROTAC
,
Small molecule
,
Targeted protein degradation
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics